Laura Gombošová
Clostridium difficile infections (CDI) of the bowel are caused by gram positive anaerobic bacterium Clostridium difficile. They result from recent systemic antibiotic therapy. Lately there has been observed growth of their occurrence and increase of morbidity and mortality. CDI frequently occurs among immunocompromised, elderly polymorbid patients. Diagnostics and treatment of Clostridium difficile infections is based on the recent Slovak guidelines from August 2012. In the treatment there is used metronidazole, vancomycin, and rarely teicoplanin. The new drug is fidaxomicin, which has some advantages in comparison with vancomycin. Its benefit is the possibility of concomitant administration with systemic antibiotics, which triggered Clostridium difficile infections of the bowel.